DiaMedica Therapeutics Inc
NASDAQ:DMAC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Equitable Holdings Inc
NYSE:EQH
|
US |
DiaMedica Therapeutics Inc
Capital Expenditures
DiaMedica Therapeutics Inc
Capital Expenditures Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Capital Expenditures | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
DiaMedica Therapeutics Inc
NASDAQ:DMAC
|
Capital Expenditures
-$41k
|
CAGR 3-Years
10%
|
CAGR 5-Years
-59%
|
CAGR 10-Years
-31%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Capital Expenditures
-$1.2B
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-9%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Capital Expenditures
-$563m
|
CAGR 3-Years
8%
|
CAGR 5-Years
3%
|
CAGR 10-Years
3%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Capital Expenditures
-$1.9B
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
-12%
|
|
|
Exact Sciences Corp
NASDAQ:EXAS
|
Capital Expenditures
-$209.7m
|
CAGR 3-Years
1%
|
CAGR 5-Years
15%
|
CAGR 10-Years
-25%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Capital Expenditures
-$437.6m
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-25%
|
|
DiaMedica Therapeutics Inc
Glance View
DiaMedica Therapeutics, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. The company is headquartered in Minneapolis, Minnesota and currently employs 14 full-time employees. The company went IPO on 2008-01-04. The firm is focused on developing treatments for neurological and kidney diseases, such as acute ischemic stroke (AIS) and chronic kidney disease (CKD). The firm's lead product DM199 mimics the behavior of naturally occurring human kallikrein-1 (KLK1) proteins to preserve and restore circulation to stroke-damaged tissue and improve overall kidney function. KLK1 is a serine protease, or protein, produced primarily in the kidneys, pancreas and salivary glands. DM199 therapy has the potential to improve circulation and overall function of critical systems, as well as reduce inflammation and oxidative stress. The firm also has other product pipelines for IgA Nephropathy and African Americans with CKD.
See Also
What is DiaMedica Therapeutics Inc's Capital Expenditures?
Capital Expenditures
-41k
USD
Based on the financial report for Sep 30, 2025, DiaMedica Therapeutics Inc's Capital Expenditures amounts to -41k USD.
What is DiaMedica Therapeutics Inc's Capital Expenditures growth rate?
Capital Expenditures CAGR 10Y
-31%
Over the last year, the Capital Expenditures growth was -95%. The average annual Capital Expenditures growth rates for DiaMedica Therapeutics Inc have been 10% over the past three years , -59% over the past five years , and -31% over the past ten years .
